



**BIOGRAPHICAL SKETCH**  
Ioannis Charalampopoulos

**NAME: Ioannis Charalampopoulos**

Personal Webpages:

<https://med.uoc.gr/en/charalampopoulos-ioannis-en/>

<https://www.imbb.forth.gr/en/research-en/neurosciences/item/3677-ioannis-charalampopoulos>

<https://www.linkedin.com/in/charalampoulosioannis/>

**POSITION TITLE:**

- **Professor of Pharmacology, Medical School, University of Crete & Clinical Pharmacology Laboratory, University General Hospital (PAGNI)**
- **Researcher at Institute of Molecular Biology and Biotechnology (IMBB), Foundation of Research and Technology Greece (FORTH)**
- **Co-Founder of the spin-off company [ReNeuroCell Therapeutics](#)**

**EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Biology Dept., University of Patras	BSc	06/1997	Biology
Medical School, University of Crete	MSc	09/2000	Neuroscience
Medical School, University of Crete	PhD	12/2004	Neuropharmacology
Neuroscience Dept., Karolinska Institutet	Postdoctoral	09/2007	Molecular Neurobiology

**A. Positions and Honors.**

**Academic – Professional Positions**

- 2005-2007: Post-doctoral fellow at Molecular Neurobiology Lab (PI: Prof. Carlos F. Ibáñez), Dept. of Neuroscience, Karolinska Institutet, Stockholm, Sweden
- 2007-2010: Research Scientist, Dept. of Pharmacology, Medical School, University of Crete
- 2010-2014: Lecturer in Pharmacology, Medical School, University of Crete.
- 2014-2019: Assistant Professor of Pharmacology, Medical School, University of Crete
- 2018-present: Researcher/Group Leader, Institute of Molecular Biology and Biotechnology (IMBB), Foundation of Research and Technology, Hellas (FORTH)
- 2019-2023: Associate Professor of Pharmacology, Medical School, University of Crete
- 2021-2024: Director of the Graduate Program in Neurosciences, Medical School, University of Crete
- 2023-present: Professor of Pharmacology, Medical School, University of Crete
- 2024-present: Co-founder of ReNeuroCell Therapeutics, spin-off company of FORTH and UoC

**Other Experience and Professional Memberships**

- Associate Editor at *Neuropharmacology (specialty section of Frontiers in Neuroscience, Frontiers in Neurology, Frontiers in Pharmacology and Frontiers in Psychiatry)* and member of the Editorial Board of *Pharmacology Research & Perspectives* & *Biomedicines*.
- *Co-Editor at the Special Issue of Frontiers in Endocrinology (Lausanne), 2024: "Steroid receptors in neuron and glia."*
- Reviewer in >30 journals including Nature Communications, Advanced Science, Cell Reports Medicine, Biomaterials, Cell Death and Disease, etc.

Member of the following Scientific Societies:

- Federation of European Biochemical Societies (FEBS).
- Federation of European Neuroscience Societies (FENS).
- Hellenic Brain Council (HBC)
- International Brain Research Organization (IBRO).
- Hellenic Society of Molecular Biology and Biochemistry.
- Hellenic Society for Neuroscience.
- Hellenic Society of Gene Therapy and Regenerative Medicine

#### **Honors**

- Invited speaker in >25 international and national meetings, (e.g. FENS Meeting, Gordon Research Conference for Neurotrophic Factors, Hellenic Initiative Against Alzheimer's Disease, Hellenic Neuroscience Society, Hellenic Society of Gene Therapy and Regenerative Medicine, Hellenic Society of Molecular Biology and Biotechnology, Greek Society of Basic and Clinical Pharmacology, NGF Meeting, Golden Helix Symposium, COST actions)
- 12 Awards in international and national meetings for best oral or poster presentations

#### **B. Selected peer-reviewed publications**

85 peer-reviewed Medline papers (all PubMed papers at: <https://pubmed.ncbi.nlm.nih.gov/?term=Charalampopoulos+I%5BAuthor%5D+NOT+Agricul&sort=date&size=100>)

**h index: 36, Total Citations: >3500**

Selected Publications:

1. Chanoumidou K, Zota I, Papadopoulou MA, Konstantinou C, Tsimpolis A, Tsagliotis E, Tziortziou M, Ntarntani K, Grünewald A, Lavigne MD, Gravanis A, **Charalampopoulos I. *Stem Cell Res Ther.* 2026 Mar 21. (\*Corresponding Author).**
2. Papadopoulou MA, Chanoumidou K, Peteinareli M, Tsaglioti E, Michalaki K, Lavigne MD, **Charalampopoulos I. *Alzheimers Res Ther.* 2026 Feb 20. (\*Corresponding Author).**
3. Maria Kokkali, Kanelina Karali, Evangelia Thanou, Maria Anna Papadopoulou, Ioanna Zota, Alexandros Tsimpolis, Paschalis Efstathopoulos, Theodora Calogeropoulou, Ka Wan Li, Kyriaki Sidiropoulou, Achille Gravanis, **Ioannis Charalampopoulos. *Molecular Psychiatry, Jun;30(6) 2025 (\*Corresponding Author).***
4. **Charalampopoulos I**, Vicario A, Pediaditakis I, Gravanis A, Simi A, Ibáñez CF. *Cell Rep.* 2012 Dec 27;2(6):1563-70
5. Lazaridis I.\*, **Charalampopoulos I\***, Alexaki VI, Avlonitis N, Pediaditakis I, Efstathopoulos P, Calogeropoulou T, Castanas E, Gravanis A. *PLoS Biol.*, Vol 9(4), 2011, (\*equal contributors)
6. Vilar M\*, **Charalampopoulos I\***, Kenchappa RS\*, Simi A\*, Karaca E, Reversi A, Choi S, Bothwell M, Mingarro I, Friedman W, Schiavo G, Bastiaens P, Verveer P, Carter BD, Ibáñez CF. *Neuron*, 2009, 62(1): 72-83 (\* equal contributors)
7. **Charalampopoulos I**, Remboutsika E, Margioris AN, Gravanis A. *Trends Endocrinol Metab.* 2008, 19(8):300-7.
8. **Charalampopoulos I**, Tsatsanis C, Dermitzaki E, Alexaki VI, Castanas E, Margioris AN, Gravanis A. *PNAS*, 2004, 101:8209-14

**Patent Application:** PCT (International Publication Number): WO 2008/155534 A2  
EPO-UK 711948,0: Neuroprotective synthetic spiro-neurosteroids.

### C. Recent Funding

- 1. Title and Reference Number of the Grant:** “SoftReach: Minimally Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Delivery for Neurological Disorders” (101099145).  
**Funding Agency and Funding Scheme:** HORIZON-European Innovation Council (EIC)-2022-PATHFINDER01-European Commission  
**Amount of grant for the Team:** 1.010.000€  
**Start date and end date of the grant:** 2023-2026
- 2. Title and Reference Number of the Grant:** National Flagship Project for elucidating the genetic basis of the neurodegenerative diseases Alzheimer's and Parkinson's, for detecting reliable biomarkers and for developing innovative technologies and therapeutic strategies for precision medicine.  
**Funding Agency and Funding Scheme:** General Secretary of Research and Innovation, Ministry of Development  
**Amount of grant for the Team:** 610.000€  
**Start date and end date of the grant:** 2024-2026
- 3. Title and Reference Number of the Grant:** Neuroinflammation on chip  
**Funding Agency and Funding Scheme:** Institute of Pharmacological Research and Technology (IFET)  
**Amount of grant for the Team:** 122.000€  
**Start date and end date of the grant:** 2023-2025
- 4. Title and Reference Number of the Grant:** Studying the role of the p75 neurotrophin receptor in hyperglycemic conditions.  
**Funding Agency and Funding Scheme:** Bodossakio Foundation  
**Amount of grant for the Team:** 48.000€  
**Start date and end date of the grant:** 2022-2024
- 5. Title and Reference Number of the Grant:** Dissecting the role of p75 neurotrophin receptor in the hippocampal adult neurogenesis as a novel therapeutic application against Alzheimer's Disease. KA10490  
**Funding Agency and Funding Scheme:** Hellenic Foundation of Research and Innovation, 1st Call for H.F.R.I. Research Projects to Support Faculty Members & Researchers and Procure High-Value Research Equipment  
**Amount of grant for the Team:** 180.000€.  
**Start date and end date of the grant:** 2019 -2023